About
Dual-Action Biologics, Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBoston & New England
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
942
By Phase
PHASE2/PHASE3: 1PHASE1: 1
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06788990Lead Sponsor
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
PHASE2/PHASE3Recruiting
650 participants
Started: Jan 28, 2025 · Completed: Jul 31, 2029
NCT04429542Lead Sponsor
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
PHASE1Recruiting
292 participants
Started: Jun 1, 2020 · Completed: Jun 1, 2027
Locations (1)
Headquarters
Boston, MA, United States
Map
Loading map...